Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JACDS to Strengthen Support to Ensure Compliance in Sale of OTC Drugs
February 6, 2012
- It Is Difficult to Check Off-Label Use of Generics Approved for Indications Different from Those of Original Drugs: Medical Bill Payment Fund
February 1, 2012
- JPMA to Make Proposals on Pricing of Long-Listed Drugs to CSIMC: President Teshirogi
January 31, 2012
- BG Kansai to Establish Service Hub to Support Use of Supercomputers in Drug Discovery
January 31, 2012
- MHLW, JPWA Hold Public-Private Dialogue on Distribution Improvement
January 30, 2012
- JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
January 27, 2012
- JPA Supports Ban on “Dispensing Point” Services at Pharmacies
January 26, 2012
- JSMI to Seek Expansions of OTCs by Appealing Preventive Effects in 2012
January 24, 2012
- JPMA to Focus on Thorough Enforcement of Compliance in Next Fiscal Year
January 20, 2012
- JPMA to Discuss State of Long-Listed Products Over a Year Ahead of FY2014 Revision
January 19, 2012
- JPMA to Set Transparency Guideline for Relationships with Patient Organizations, Disclose Information from FY2013
January 19, 2012
- JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
- FPMAJ Detects Radioactive Substances in 2 Crude Raw Material Samples
January 17, 2012
- JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
- JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
- PMAT President Matsuda Says Permanent Introduction of Premium is Priority Issue
January 10, 2012
- FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
- New Year’s Remarks: We wish each of our stakeholders a very Happy and Healthy New Year 2012.
January 5, 2012
- 2012 New Year’s Message: The Ultimate Winner of the Medical Policy Changes is the Patient
January 5, 2012
- New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…